Efficacy of low-dose mifepristone in patients with thrombotic disorders complicated by heavy menstrual bleeding

Zhonghua Fu Chan Ke Za Zhi. 2025 Dec 25;60(12):943-950. doi: 10.3760/cma.j.cn112141-20250415-00149.ABSTRACTObjective: To evaluate the efficacy and safety of low-dose mifepristone (10-25 mg) in patients with thromboembolic disorders complicated by heavy menstrual bleeding (HMB). Methods: The data of

X X L Jiang

Non-linear association of coagulation factor XI with mortality

Med. 2025 Dec 26:100934. doi: 10.1016/j.medj.2025.100934. Online ahead of print.ABSTRACTBACKGROUND: Coagulation factor XI (FXI) influences both thrombotic risk and myocardial function, making its relationship with mortality crucial for guiding therapies, especially in coronary artery disease (CAD).M

K Katsiaryna Prystupa

Advances in coagulation peptides: Exploring diverse functions from hemostasis to disease treatment

Colloids Surf B Biointerfaces. 2025 Dec 23;260:115383. doi: 10.1016/j.colsurfb.2025.115383. Online ahead of print.ABSTRACTCoagulation dysfunction and bleeding control remain major challenges in trauma, surgery, and interventional therapy. Millions of patients die from excessive blood loss every year

W Wenwen Ma

A pedigree analysis of deep venous thrombosis caused by rare compound heterozygous PROC mutations combined with a heterozygous THBD mutation

No abstractThromb J. 2025 Dec 26. doi: 10.1186/s12959-025-00824-7. Online ahead of print.NO ABSTRACTPMID:41454398 | DOI:10.1186/s12959-025-00824-7

R Rui Tuo

Large-bore mechanical thrombectomy vs standard of care for acute high-risk pulmonary embolism: rationale and design of the PERSEVERE randomized controlled trial

Am Heart J. 2025 Dec 24:107331. doi: 10.1016/j.ahj.2025.107331. Online ahead of print.ABSTRACTBACKGROUND: Catheter-directed therapies are increasingly used to treat acute pulmonary embolism (PE). However, randomized data on reperfusion treatments, including large-bore mechanical thrombectomy (LBMT),

R Romain Chopard

Von Willebrand disease type 2A: an update

Semin Thromb Hemost. 2025 Dec 26. doi: 10.1055/a-2778-9989. Online ahead of print.ABSTRACTDysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding disorder. Type 2A VWD is a qualitative defect marked by impaired

O Omid Seidizadeh

Five-Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research

Haemophilia. 2025 Dec 26. doi: 10.1111/hae.70193. Online ahead of print.ABSTRACTINTRODUCTION: To enhance the treatment quality in haemophilia centres (HC), the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research (GTH) started in 2017 the development of guidelines to define the

H Hermann Eichler

(Dis)solving the inflammatory neutrophil extracellular traps of venous thromboembolism with P2Y14 antagonists

No abstractEur Heart J. 2025 Dec 26:ehaf985. doi: 10.1093/eurheartj/ehaf985. Online ahead of print.NO ABSTRACTPMID:41451758 | DOI:10.1093/eurheartj/ehaf985

J Jürg H Beer

von Willebrand disease combined with other hemostasis disorders: an overlooked clinical entity

Res Pract Thromb Haemost. 2025 Nov 17;9(8):103259. doi: 10.1016/j.rpth.2025.103259. eCollection 2025 Nov.ABSTRACTvon Willebrand disease (VWD) is common, affecting ∼1% of the general population. Due to this relatively high prevalence, it can co-occur with other coagulation disorders. However, combine

O Omid Seidizadeh

Evaluation of the Use of Primary Prevention Aspirin in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant for Stroke Prevention

Ann Pharmacother. 2025 Dec 26:10600280251401892. doi: 10.1177/10600280251401892. Online ahead of print.ABSTRACTBACKGROUND: Current guidelines advise against use of aspirin for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with increased bleeding risk, including use

S Storee A Yzaguirre

Evaluation of Argatroban in Sepsis-Induced Coagulopathy: A Retrospective Study Based on MIMIC-IV Database

Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251326095. doi: 10.1177/10760296251326095. Epub 2025 Dec 25.ABSTRACTBackgroundSepsis-Induced Coagulopathy (SIC) is common complications of sepsis in intensive care unit (ICU) patients. It has a significant impact on the prognosis of patients with seps

J Jiaqi Tang

Follow-up Algorithm for Detecting Chronic Sequelae of Pulmonary Embolism: Diagnostic Performance and Possible Limitations

J Thromb Haemost. 2025 Dec 23:S1538-7836(25)00912-2. doi: 10.1016/j.jtha.2025.11.029. Online ahead of print.ABSTRACTBACKGROUND: Survivors of pulmonary embolism (PE) can suffer from serious long-term complications; a standardized follow-up diagnostic strategy may lead to their early identification.OB

I Ioannis T Farmakis

Screening, Diagnosis, and Management of Pediatric Post-Thrombotic Syndrome Following Extremity Thrombosis

J Thromb Haemost. 2025 Dec 23:S1538-7836(25)00917-1. doi: 10.1016/j.jtha.2025.11.031. Online ahead of print.ABSTRACTPediatric post-thrombotic syndrome (PTS) is the most common long-term complication of deep vein thrombosis (DVT) in children, which is in turn the most common thrombotic event in child

A Avila Laura

PlateChek: A Surface-functionalized Dielectric Microsensor for Specific Detection of Platelet-related Hemostatic Impairment in Whole Blood

J Thromb Haemost. 2025 Dec 23:S1538-7836(25)00907-9. doi: 10.1016/j.jtha.2025.12.008. Online ahead of print.ABSTRACTBACKGROUND: Platelet count or function defects can result in hemostatic impairment, leading to life-threatening bleeding complications. While platelet transfusions are used to treat su

D Dante Disharoon

Identification of coagulation-related hub genes in ischemic stroke based on bioinformatics integration analysis and investigation of their immune regulatory mechanisms

Eur J Med Res. 2025 Dec 24;30(1):1256. doi: 10.1186/s40001-025-03477-4.ABSTRACTBACKGROUND: Ischemic stroke (IS) is a cerebrovascular disease resulting from insufficient blood supply to specific areas of the brain, often due to atherosclerosis and thrombosis. While the association between polymorphis

H Hepeng Li

Thrombin generation profiling in rare coagulation factor deficiencies: associations with bleeding severity and potential for screening

J Thromb Haemost. 2025 Dec 22:S1538-7836(25)00906-7. doi: 10.1016/j.jtha.2025.11.025. Online ahead of print.ABSTRACTINTRODUCTION: Rare coagulation factor deficiencies (RCFDs) can cause significant bleeding, but APTT and PT may not detect abnormalities, and factor activity measurements do not predict

B Bauke Haisma

Neutrophil Extracellular Traps Promote Platelet-Driven Contraction of Inflammatory Blood Clots via Local Generation of Endogenous Thrombin and Softening of the Fibrin Network

Cells. 2025 Dec 18;14(24):2018. doi: 10.3390/cells14242018.ABSTRACTImmunothrombosis can substantially affect the course and outcomes of severe infections and immune-mediated diseases. While inflammatory thrombi are neutrophil-rich, impact of neutrophils on clot contraction, a key modulator of thromb

S Shakhnoza M Saliakhutdinova

Protease-activated receptor 4 deficiency increases mortality, intracranial bleeding, and blood-brain barrier impairment following traumatic brain injury in mice

Res Pract Thromb Haemost. 2025 Oct 30;9(8):103238. doi: 10.1016/j.rpth.2025.103238. eCollection 2025 Nov.ABSTRACTBACKGROUND: Protease-activated receptors (PARs), comprising PAR1 to PAR4, play a critical role in hemostasis and are considered potential therapeutic targets. Clinical trials have evaluat

L Leonie S Link

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms

Leukemia. 2025 Dec 23. doi: 10.1038/s41375-025-02836-8. Online ahead of print.ABSTRACTThrombotic risk assessment is crucial in newly diagnosed essential thrombocythemia (ET) and polycythemia vera (PV) patients to guide cytoreductive therapy. We assessed whether thromboinflammation biomarkers would b

A Alexandre Guy

Trends in Catheter-Directed Therapy and In-Hospital Outcomes Among Patients with Acute Pulmonary Embolism: Insights from a Multicenter National Quality Assurance Database Registry

Eur Heart J Acute Cardiovasc Care. 2025 Dec 23:zuaf169. doi: 10.1093/ehjacc/zuaf169. Online ahead of print.ABSTRACTBACKGROUND: Multidisciplinary pulmonary embolism response teams (PERT) are being established in hospitals worldwide to address the increasing complexity in acute PE management.AIM: To i

I Ioannis T Farmakis

Guideline for the management of hepatitis B and C infection and subsequent liver disease surveillance (where indicated) in people with congenital bleeding disorders: A joint guideline from the British Society of Haematology and the British Viral Hepatitis Group

Br J Haematol. 2025 Dec 23. doi: 10.1111/bjh.70283. Online ahead of print.ABSTRACTThis is a new British Society of Haematology (BSH) guideline which focuses on the management of hepatitis B and C (HBV and HCV) infection affecting people with bleeding disorders (PwBD), including those who cleared the

A Ashley Brown

Type 3 von Willebrand disease in Ethiopia: a comprehensive literature review and report of the first three cases

Thromb J. 2025 Dec 22. doi: 10.1186/s12959-025-00819-4. Online ahead of print.ABSTRACTType 3 von Willebrand disease (VWD) is the rarest and most severe form of VWD, resulting from a complete loss of function of the von Willebrand factor (VWF). This disease presents bleeding symptoms that are charact

G Gashaw Arega

Outcomes of non-valvular atrial fibrillation elderly patients maintained on VKAs' treatment compared to patients switched to DOACs: results from the START2-AF registry

Intern Emerg Med. 2025 Dec 22. doi: 10.1007/s11739-025-04227-4. Online ahead of print.ABSTRACTDirect oral anticoagulants (DOAC) have similar efficacy for stroke prevention in patients with non-valvular atrial fibrillation (AF) with improved safety. Recently, a higher bleeding risk was reported when

C Chiara Cappugi

Femoral vein occlusion after VASCADE MVP resolved without surgery: a case report

Eur Heart J Case Rep. 2025 Nov 8;9(12):ytaf581. doi: 10.1093/ehjcr/ytaf581. eCollection 2025 Dec.ABSTRACTBACKGROUND: VASCADE MVP® is a vascular closure device developed to achieve haemostasis of large-bore venous access by deploying a collagen patch in the subcutaneous tissue. While its efficacy and

M Masaki Honda